drugset / Trial / NCT04002349
Study of Medication for Nonallergic Rhinitis (NAR) Based on Cluster Analysis
Unknown
80 enrolled
Beijing Tongren Hospital
Beijing Institute of Otolaryngology · collabShanghai Johnson & Johnson Pharmaceuticals, Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Chronic rhinitis (CR) is one of the most common nasal mucosal diseases in the world. In China, about 140 million people suffer from this disease. Chronic rhinitis can lead to severe economic and social burden, as well as the potential risk of developing other chronic diseases such as asthma and chronic sinusitis. Therefore, it is of great significance to explore the classification and treatment strategies of chronic rhinitis in order to improve the health level of Chinese people.
Timeline
- Start
- 2019-07-01
- Primary completion
- 2019-12-31
- Completion
- 2020-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Budesonide | Small molecule | 2 unknown | Intranasal |
| Subject | Levocabastine | Small molecule | 2 unknown | Intranasal |
Indications
No indication recorded.